US 11,690,871 B2
Animal plasma or fractions thereof for use in treating cognitive impairment disorders in humans and companion animals
Francisco Javier Polo Pozo, Barberá del Vallés (ES); Louis Edward Russell, Ankeny, IA (US); María Carmen Rodríguez Canel, Barcelona (ES); Joy Marlene Campbell, Ames, IA (US); Joe David Crenshaw, Windsor Heights, IA (US); Miquel Moretó Pedragosa, Esplugues del Llobregat (ES); Anna Pérez Bosque, Igualada (ES); and Lluïsa Miró Martí, Barcelona (ES)
Assigned to APC EUROPE SLU, Barcelona (ES)
Appl. No. 16/613,951
Filed by APC EUROPE SLU, Granollers (ES)
PCT Filed May 17, 2018, PCT No. PCT/EP2018/062915
§ 371(c)(1), (2) Date Nov. 15, 2019,
PCT Pub. No. WO2018/211014, PCT Pub. Date Nov. 22, 2018.
Claims priority of application No. ES201730705 (ES), filed on May 18, 2017.
Prior Publication US 2021/0260112 A1, Aug. 26, 2021
Int. Cl. A61K 35/16 (2015.01); A61P 25/28 (2006.01); A61K 35/57 (2015.01); A61K 38/17 (2006.01); A61K 38/40 (2006.01)
CPC A61K 35/16 (2013.01) [A61K 35/57 (2013.01); A61K 38/1703 (2013.01); A61K 38/1722 (2013.01); A61K 38/1741 (2013.01); A61K 38/1774 (2013.01); A61K 38/40 (2013.01); A61P 25/28 (2018.01)] 27 Claims
 
1. A method of treating a cognitive impairment disorder in a human or companion animal subject, said method comprising:
a. administering to said subject one or more cognitive functioning tests to identify a subject suffering from a cognitive impairment disorder; and
b. orally administering to said subject a therapeutically effective amount of an animal plasma composition;
wherein said administration provides an improvement in said subject's results in said one or more cognitive impairment tests.